Visudyne Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Verteporfin

Indications/Uses

Predominantly classic or occult subfoveal choroidal neovascularization due to age-related macular degeneration or w/ subfoveal choroidal neovascularization caused by other macular disease.

Click to view Visudyne detailed prescribing information

Dosage/Direction for Use

1st step: 6 mg/m² as 10-min IV infusion. 2nd step: Light activation at 15 min after start of infusion. Recurrent CNV leakage Re-evaluate every 3 mth.

Click to view Visudyne detailed prescribing information

Overdosage

View Visudyne overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity. Porphyria.

Click to view Visudyne detailed prescribing information

Special Precautions

Discontinue use if anaphylactic or other serious allergic reaction occurs. Photosensitivity up to 48 hr after infusion. Severe decreased vision (equiv ≥4 lines) w/in 1 wk after treatment. Avoid extravasation. May affect ability to drive or use machines. Moderate to severe hepatic impairment or biliary obstruction. Renal impairment. Pregnancy & lactation. Not to be used in childn.

Click to view Visudyne detailed prescribing information

Use In Pregnancy & Lactation

Click to view Visudyne detailed prescribing information

Adverse Reactions

Retinal detachment, haemorrhage, ischaemia & oedema, vitreous haemorrhage, visual impairment & field defect, reduced visual acuity, nausea, asthenia, inj site oedema, inflammation, extravasation, pain, hypersensitivity & haemorrhage, pyrexia, back & chest pain, hypoaesthesia, photosensitivity reaction, HTN, syncope, malaise, headache, dizziness, dyspnoea, rash, urticaria, pruritus.

Click to view Visudyne detailed prescribing information

Drug Interactions

Increased potential photosensitivity reactions w/ photosensitising agents. Enchanced tissue-uptake w/ Ca-channel blockers, polymyxin B, radiation therapy. Decreased activity w/ antioxidants (eg, β-carotene) or free radical scavengers (eg, dimethylsulfoxide, formate, mannitol, alcohol). Antagonized action w/ vasodilators & drugs diminishing clotting & platelet aggregation (eg, thromboxane A2 inhibitors).

Click to view Visudyne detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Visudyne detailed prescribing information

Storage

View Visudyne storage conditions for details to ensure optimal shelf-life.

Description

View Visudyne description for details of the chemical structure and excipients (inactive components).

Action

View Visudyne mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Other Eye Preparations

ATC Classification

S01LA01 - verteporfin ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.

Regulatory Classification

Presentation/Packing

Form

Visudyne infusion 15 mg

Packing/Price

1's

Visudyne

verteporfin

Manufacturer:

Zuellig Pharma

Distributor:

Zuellig Pharma